1. Home
  2. BOLT vs XIN Comparison

BOLT vs XIN Comparison

Compare BOLT & XIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLT
  • XIN
  • Stock Information
  • Founded
  • BOLT 2015
  • XIN 1997
  • Country
  • BOLT United States
  • XIN China
  • Employees
  • BOLT N/A
  • XIN N/A
  • Industry
  • BOLT Biotechnology: Pharmaceutical Preparations
  • XIN Homebuilding
  • Sector
  • BOLT Health Care
  • XIN Consumer Discretionary
  • Exchange
  • BOLT Nasdaq
  • XIN Nasdaq
  • Market Cap
  • BOLT 16.8M
  • XIN 16.2M
  • IPO Year
  • BOLT 2021
  • XIN N/A
  • Fundamental
  • Price
  • BOLT $0.40
  • XIN $2.62
  • Analyst Decision
  • BOLT Hold
  • XIN
  • Analyst Count
  • BOLT 5
  • XIN 0
  • Target Price
  • BOLT $1.13
  • XIN N/A
  • AVG Volume (30 Days)
  • BOLT 146.3K
  • XIN 11.4K
  • Earning Date
  • BOLT 05-13-2025
  • XIN 01-01-0001
  • Dividend Yield
  • BOLT N/A
  • XIN N/A
  • EPS Growth
  • BOLT N/A
  • XIN N/A
  • EPS
  • BOLT N/A
  • XIN N/A
  • Revenue
  • BOLT $7,690,000.00
  • XIN $667,143,185.00
  • Revenue This Year
  • BOLT N/A
  • XIN N/A
  • Revenue Next Year
  • BOLT $77.45
  • XIN N/A
  • P/E Ratio
  • BOLT N/A
  • XIN $0.30
  • Revenue Growth
  • BOLT N/A
  • XIN N/A
  • 52 Week Low
  • BOLT $0.38
  • XIN $2.24
  • 52 Week High
  • BOLT $1.48
  • XIN $7.05
  • Technical
  • Relative Strength Index (RSI)
  • BOLT 40.42
  • XIN 44.57
  • Support Level
  • BOLT $0.38
  • XIN $2.58
  • Resistance Level
  • BOLT $0.47
  • XIN $2.75
  • Average True Range (ATR)
  • BOLT 0.04
  • XIN 0.16
  • MACD
  • BOLT -0.00
  • XIN -0.01
  • Stochastic Oscillator
  • BOLT 18.81
  • XIN 31.58

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About XIN Xinyuan Real Estate Co Ltd

Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.

Share on Social Networks: